![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the terms of the agreement, Faran will receive the exclusive rights to market Firibastat for the treatment of difficult-to-treat / resistant hypertension in Greece.
Lead Product(s): Firibastat
Therapeutic Area: Cardiology/Vascular Diseases Product Name: QGC001
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Quantum Genomics
Deal Size: Undisclosed Upfront Cash: $12.1 million
Deal Type: Collaboration December 15, 2020